Akerna (KMDA) Upgraded by Zacks Investment Research to Buy

Akerna stock has undergone multiple analysts rating changes in the recent past.  Akerna Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Akerna traded down -$0.14 on Tuesday, reaching $2.84. 336 shares of the stock traded hands, compared to its average volume of 897884. Shares of Akerna were trading at $2.84 on Tuesday. The firm’s 50 day moving average is $5.37 and its 200 day moving average is $5.99.Akerna has a 12 month low of $2.83 and a 12 month high of $10.44. While on yearly highs and lows, Akerna’s today has traded high as $3.08 and has touched $2.83 on the downward trend. See More Analyst Rating at: RATING

Akerna Earnings and What to expect: 

Kamada last released its earnings data on August 11th, 2021. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by $0.03. The company had revenue of $24.24 million for the quarter, compared to analysts’ expectations of $25.69 million. Kamada has generated $0.38 earnings per share over the last year ($0.27 diluted earnings per share) and currently has a price-to-earnings ratio of 19.4. Earnings for Kamada are expected to grow by 30.00% in the coming year, from $0.10 to $0.13 per share. Kamada has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 10th, 2021 based off prior year’s report dates.

Earnings for Kamada are expected to grow by 30.00% in the coming year, from $0.10 to $0.13 per share. The P/E ratio of Kamada is 19.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.78. The P/E ratio of Kamada is 19.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 32.64. Kamada has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Akerna (KMDA) Moving Average Technical Analysis

5 day Moving Average is $5.24 And 5 day price change is -$0.05 (-0.95%)  with average volume for 5 day average is 26,920. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $5.31 and 20 day price change is -$0.08 (-1.50%) and average 20 day moving volume is 24,660. 50 day moving average is $5.37  and 50 day price change is -$0.30 ( -5.42%)  and with average volume for 50 days is : 40,174. 200 day moving average is $5.99  and 200 day price change is -$1.36 (-20.61%)  and with average volume for 200 days is : 113,604.

Other owners latest trading in Akerna :

  • On 8/23/2021 shares held by Morgan Stanley were 206,619 which equates to market value of $1.20M and appx 0.00% owners of Akerna
  • On 8/17/2021 shares held by Millennium Management LLC were 12,478 which equates to market value of $73K and appx 0.00% owners of Akerna
  • On 8/16/2021 shares held by Morgan Stanley were 206,619 which equates to market value of $1.20M and appx 0.00% owners of Akerna
  • In total Institutional ownership equates to Institutional Ownership Percentage: 17.40% for Akerna

See More Analyst Rating at: RATING